Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study
about
Hyperphosphatemia Management in Patients with Chronic Kidney DiseaseCardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicabilityElevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort.Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney diseaseFibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseTertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.Associations of epicardial fat with coronary calcification, insulin resistance, inflammation, and fibroblast growth factor-23 in stage 3-5 chronic kidney disease.Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional studyFibroblast growth factor 23 and risk of incident stroke in community-living adultsFibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathyFibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.Correlates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals.Urine fibroblast growth factor 23 levels in hypertensive children and adolescents.Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse boneLongitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.High-Flux Hemodialysis Benefits Hemodialysis Patients by Reducing Serum FGF-23 Levels and Reducing Vascular Calcification.Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney diseaseImpaired vitamin D metabolism in CKDFractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomesHigh Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study.Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study.Optimization of Bone Health in Children before and after Renal Transplantation: Current Perspectives and Future Directions.Clinical practice. Fibroblast growth factor (FGF)23: a new hormone.Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.Is fibroblast growth factor 23 a harbinger of mortality in CKD?Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.FGF-23 and secondary hyperparathyroidism in chronic kidney disease.Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy.Prognostic importance of fibroblast growth factor-23 in dialysis patients.Factors related to nephrotic-range proteinuria in late-stage chronic kidney disease patients with diabetes mellitus.Fibroblast growth factor 23 is a predictor of aortic artery calcification in maintenance hemodialysis patients.
P2860
Q26743842-11C035D3-860C-403F-9D67-E02CCC41E335Q28081407-1009B7D3-0C8A-47EB-8CC2-CB9318E97937Q30427104-DE74C8F2-9BD0-4414-8298-16BF4737A8C1Q34244300-0017BF54-548E-4B40-B7D5-A533EBDAE81FQ34406428-92326F7A-931C-4CA9-BB2B-C35FED28816FQ34421217-DBE680FA-1C03-4B3C-8F17-33C5CD392583Q34500628-EE994425-089B-47B8-9EB9-3D93EE7EA897Q34563990-F63DFAC1-73E5-49A9-A6AD-8D91DBA675CBQ34588377-61DDA6AF-291C-4207-8986-C8797CCDB462Q35019943-1C91B325-49F2-4E62-8718-D03DD567E63AQ35099518-4455F2FE-964A-45E2-873E-3D6CC48E2373Q35837789-C67C8C96-655F-46D0-B316-466A5250E071Q35917428-80791987-CEC8-4C79-8318-DF0731CC8B8EQ35967107-1BC7FA33-4CEF-4497-86B6-C98B61531F82Q36016861-1EECDD15-DE31-4BA2-9C8E-6003CD3F33F1Q36077946-0A535A62-4E04-4E14-A450-AF59074377D2Q36095111-FB4B5389-4207-4BF0-8FCE-92A6A85D57B3Q36208896-D3E90223-74D7-4BE1-A347-D6A42495CDE0Q36227410-4E7BA7EA-5DA8-4EED-B053-6BDA126D7B47Q36287699-324C19C9-74DE-40FD-A82F-ADD5D07B38BCQ36516443-748D0B24-6121-4566-86D6-DBE6C73C3264Q36668070-CE8C1A0A-0C52-4461-8996-5B6C00935CCFQ36719260-ABDCABD6-A78E-472C-9E04-C2C889836665Q36822751-A2554C66-B2B9-4DEC-8244-3DA9AA6A253FQ37071263-8DF1D5E4-6643-4108-85E3-4C1641837544Q37136264-B604F9AD-E2CA-4542-A5E3-A04599D117CFQ37342971-CF12ADCB-D546-4581-BEA1-59B8C80BF594Q37416887-8D5B3846-A64A-42C7-AC4A-5CF34DD2DCA2Q37589683-04FEAF33-3178-422F-BEF6-07AE4214CC3CQ37598894-029D0831-F6DE-4512-BF0F-618C6EF7A02DQ37824821-5F5291CB-6B5E-471D-927A-BA695B3C533AQ37832285-45B62F02-36F2-4586-8991-AE1006A32A70Q37851395-CCA2ACBE-D88D-4A94-8F1A-412F700E0719Q38009044-5BAC17BA-7B6B-400C-BFF1-3B1B1CBDC6E3Q38123396-39386838-2C75-4DDF-857B-06664CD7D094Q40115641-55963251-EC11-403F-A329-A6A7DCD693F5Q41831146-98599EE6-EF2E-4F26-BD65-E81DCD8433BAQ44945901-3516EFEB-8F34-4AD9-8DAA-1398B3D2F0ABQ51071803-1AD2582B-321D-44D6-B70C-30C1CE21EC16
P2860
Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@ast
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@en
type
label
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@ast
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@en
prefLabel
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@ast
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@en
P2860
P50
P356
P1476
Fibroblast growth factor-23 an ...... tion: the Heart and Soul Study
@en
P2093
Christina L Wassel
P2860
P304
P356
10.1093/NDT/GFP699
P407
P577
2009-12-27T00:00:00Z